RNA design company Wayfinder Biosciences announced today that it raised a $3.5 million series seed round led by Notation Capital and Divergent Capital to continue its groundbreaking work in the use of RNA as a detection and therapeutic platform.
RNA is best known as a messenger that carries the blueprints for the cell’s protein machinery, as seen in the recent mRNA vaccines for SARS-CoV-2 and in the pipeline of innovative gene therapies on the horizon. RNA, however, is also a versatile cellular machine in itself. Some of RNA’s functions include regulating disease, sensing molecules, and performing CRISPR applications. Wayfinder Biosciences combines the expansive capabilities of RNA with exclusive biophysical algorithms and proprietary design rules. Thanks to Wayfinder’s platform, long-desired advanced functionality can be engineered into RNA in dramatically shorter time than existing technologies.
